SWTX SpringWorks Therapeutics Inc
784
$29.01
$0.07
(0.24%)
| Market Cap | $1.82B |
| Volume (M) | 1.55M |
| 52-Wk High | $34.16 |
| 52-Wk Low | $18.00 |
ST Data
Watchers
New Watcher Rank
SpringWorks Therapeutics (SWTX, $28.92) RSI Indicator left the overbought zone on December 05, 2023Tickeron - Stocks • about 20 hours ago
This is a signal that SWTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Share to Feed
Swiss National Bank increased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent...
STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
ProShare Advisors LLC lifted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX Free Report) by 35.6% in the 2nd quarter, according to the company in its most recent 13F...
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX Free Report) Equities researchers at Wedbush upped their FY2024 earnings per share (EPS) estimates for shares of SpringWorks Therapeutics...
This is a signal that SWTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who read more...
SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest SWTX News
SpringWorks Therapeutics (SWTX, $28.92) RSI Indicator left the overbought zone on December 05, 2023
Tickeron - Stocks • about 20 hours ago
Swiss National Bank Grows Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Zolmax • 2 days ago
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Globe Newswire • 2 days ago